Table 2.
GSLs a | Average (μmol g−1) |
Range (μmol g−1) |
CV (%) b |
---|---|---|---|
GIB | 1.50 | 0.01–5.01 | 69.93 |
PRO | 0.77 | 0.00–3.86 | 106.57 |
EPI | 0.11 | 0.00–0.26 | 36.13 |
SIN | 3.45 | 0.00–12.87 | 79.15 |
GRA | 0.62 | 0.00–3.85 | 129.88 |
GNA | 0.47 | 0.00–2.81 | 126.77 |
GER | 0.03 | 0.00–0.61 | 280.47 |
Total Aliphatic GSLs | 6.95 | 1.31–17.88 | 46.39 |
4HGBS | 0.06 | 0.00–0.29 | 85.47 |
GBS | 3.91 | 0.79–1.14 | 53.53 |
4MGBS | 0.29 | 0.00–2.57 | 94.99 |
NGBS | 0.40 | 0.05–2.00 | 84.33 |
Total Indolyl GSLs | 4.46 | 1.01–15.57 | 51.16 |
GNS | 0.09 | 0.00–0.67 | 137.77 |
Total Aromatic GSLs | 0.09 | 0.00–0.67 | 137.77 |
Total | 11.71 | 3.99–23.75 | 36.44 |
a Glucosinolate abbreviations. GSLs: glucosinolates; GIB: glucoiberin; PRO: progoitrin; EPI: epiprogoitrin; SIN: sinigrin; GRA: glucoraphanin; GNA: gluconapin; GER: glucoerucin; 4HGBS:4-hydroxyglucobrassicin; GBS: glucobrassicin; 4MGBS: 4-methoxyglucobrassicin; NGBS: neoglucobrassicin; GNS: gluconastrutiin. b CV: coefficient of variation.